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Abstract In patients with serous adenocarcinoma (SAC) of
the endometrium, we evaluated the prognostic importance
of clinicopathological parameters, DNA ploidy, and immu-
noexpression of p53, estrogen receptor (ER), progesterone
receptor (PR), and Ki-67. In a series of 73 stage I and II
SAC, DNA ploidy analysis was performed on hysterectomy
specimens using DNA image cytometry. Immunohisto-
chemical analysis of p53, ER, PR, and Ki-67 expression
was additionally performed. In the review of the histological
slides by three gynecologic pathologists, the presence of a
serous component was not agreed upon in 17 (23 %) cases.
The remaining 56 cases, consisting of pure SAC or SAC
mixed with endometrioid adenocarcinoma, were further an-
alyzed. Tumor recurrence was observed in 14 patients, and
28 patients died during the follow-up period. Patients with
diploid (n019), aneuploid (n029), and tetraploid (n08)
tumor had 5-year recurrence rates of 10, 38, and 53 %,
respectively (p00.09). A DNA ploidy parameter, 5c exceed-
ing rate, was found to be a prognostic marker for recurrence
(p00.03), progression-free survival (p<0.01), and overall
survival (p00.02). Immunoexpression of p53, ER, PR, and
Ki-67 did not have prognostic value, and the same was true
for FIGO stage, lymphovascular invasion, the extent of
myometrial invasion, and lymphadenectomy. The histolog-
ical diagnosis of SAC may be difficult in some cases.
Established clinicopathological parameters do not seem to
be strong prognosticators in stage I and II disease. A DNA
ploidy parameter, 5c exceeding rate, may be a prognostic
marker in this patient group and should be further validated
in larger series.
Keywords Serous adenocarcinoma . Endometrial
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Introduction
Endometrial carcinoma (EC), the most common gynecolog-
ical malignancy in the Western world, is considered to be a
relatively less aggressive tumor with a good prognosis.
Nearly 30 years ago, Lauchlan and Hendrickson et al. rec-
ognized a distinct histological type, serous adenocarcinoma
(SAC), which has a more aggressive behavior [1, 2]. SAC is
a rare tumor accounting for 4–10 % of all EC [3, 4]. SAC
usually arises from atrophic endometrium and therefore
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occurs in relatively older women [3, 5]. SAC differs from
endometrioid adenocarcinoma (EAC) in a number of
respects; estrogen receptor (ER) and progesterone receptor
(PR), usually present in normal endometrium and EAC, are
less frequently expressed in SAC [6]. The mutation of TP53,
coding for the tumor suppressor p53, is considered to be an
early event in SAC as the mutation has been demonstrated
in intraepithelial carcinoma [7]. Ki-67, a nuclear protein
associated with cell proliferation, is more extensively
expressed in SAC compared to EAC [8]. In contrast to
EAC, SAC has not been found to be associated with PTEN
and KRAS mutation or microsatellite instability [9]. Recent
gene expression studies have demonstrated different profiles
in SAC compared to EAC grade 1 and 2 [10]. SAC is
associated with DNA aneuploidy, and most of the tumors
show a DNA index >1.60 and a higher 5c exceeding
rate (5c ExR) than EAC [11].
The incidence of recurrence after primary therapy is
higher in SAC than EAC [12, 13]. Furthermore, SAC is
more often diagnosed at advanced stage compared to EAC
[3]. In spite of its rarity, SAC has been shown to be respon-
sible for 39 % of all EC-related deaths [4]. However, in an
accumulated multinational series of 8,033 EC patients, SAC
was found in 323 cases (4 %) with 80 % overall 5-year
survival in stage I patients [3]. This indicates that a substan-
tial number of SAC patients have a good prognosis, but
reliable prognostic indicators are lacking. In the present
study, we evaluated the prognostic role of clinicopatholog-
ical parameters, DNA ploidy, and immunohistochemical
markers in stage I and II SAC.
Materials and methods
This is a study of consecutive patients with SAC of the
endometrium referred to the Norwegian Radium Hospital
from October 1998 to December 2007. Altogether, 215
patients were diagnosed with SAC in the period, out of
which 73 stage I and II cases were available for DNA ploidy
and histological review in hysterectomy specimen. The
specimens were retrieved from the archives of the Depart-
ment of Pathology. Data regarding FIGO stage (2009), the
extent of myometrial invasion, and lymphovascular inva-
sion (LVI) were retrieved from pathological reports. Clinical
data were provided by the Department of Gynecologic
Oncology. Data on patient death were acquired from the
death register of the Central Bureau of Statistics, which
is based on the transmitted death certificates by the
patient’s physician. Simple and radical hysterectomies
were performed in 60 and 13 cases, respectively. In 29
patients, infracolic omentectomy was performed. Both
pelvic and paraaortic lymphadenectomy were done in
16 cases and only pelvic lymphadenectomy in 26 cases.
Twenty-three patients received adjuvant chemotherapy,
ten patients received radiotherapy, and five patients received
both. Patients with recurrencewere treated with chemotherapy
(six cases), radiotherapy (five cases), hormonal therapy (one
case), both chemotherapy and radiotherapy (two cases), che-
motherapy and antihormonal treatment (one case), and all
three therapeutic modalities (two cases). Ethical approval for
the study was obtained from the Regional Committee for
Medical and Health Research Ethics, Southeastern Norway.
Histologic review
All H&E slides from the area from which DNA ploidy and
immunohistochemical analysis were performed were inde-
pendently reviewed by three experienced gynecological
pathologists (BD, BR, and VA). The World Health Organi-
zation recommendation [14] was used to classify the tumors.
Pure SAC and SAC mixed with EAC were entered in the
study. Discrepant cases were discussed at a consensus
session.
DNA image cytometry
Using thick 50-μm sections from paraffin-embedded
blocks from hysterectomy specimens, a monolayer of
cells was prepared on a slide. After staining with the
Feulgen method, nuclear DNA content was measured
indirectly using Ploidy Work Station (Room4, Crowbor-
ough, UK). DNA ploidy histograms were created using
PWS classifier (Room4, Crowborough, UK). The histo-
grams were classified as diploid, aneuploid (DNA index,
DI, 1.06–1.89 and >2.10), tetraploid (DI 1.90–2.10), and
polyploid. DNA ploidy-related parameters such as DI,
5c ExR, and 9c exceeding rate (9c ExR) of the tumors
were also noted. A detailed description of the proce-
dure, DNA content measurement, and histogram classi-
fication criteria are given elsewhere [11].
Immunohistochemistry
From the formalin-fixed, paraffin-embedded tissue
blocks of the hysterectomy specimen, 4–5-μm thick
sections were cut and stained using a Dako Autostainer.
Sections were deparaffinized, and epitopes were
unmasked using Dako PT link with high pH buffer for
20 min. Endogenous peroxidase was blocked using En-
Vision FLEX Peroxidase-Blocking Reagent. The sec-
tions were incubated with primary mouse monoclonal
antibodies against p53 (1:5,000, Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA), ER (1:200, Novocastra
Laboratories Ltd, Newcastle-upon-Tyne, UK), PR
(1:300, Novocastra Laboratories Ltd.), and Ki-67
(1:200, DakoCytomation, Glostrup, Denmark) for
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30 min. EnVision FLEX+ Mouse (LINKER) was ap-
plied for 15 min for signal amplification. After applying
Dako EnVision FLEX+HRP for 30 min, diluted DAB
chromogen was applied for 10 min. The slides were
counterstained with hematoxylin and mounted. Relevant
positive and negative controls were used with each
antibody, with satisfactory results. In mixed tumors,
expression was scored only in the serous component.
Based on percentage of cells showing immunoexpres-
sion, slides were scored as negative (0–10 %), weakly
positive (11–50 %), and strongly positive (51–100 %).
Statistical analysis
Predictive Analytics SoftWare statistics 18 (SPSS Inc.,
Chicago, IL) was used for statistical analysis. All sta-
tistical tests were two-sided, and p value <0.05 was
considered as statistically significant. Progression-free
survival (PFS) was calculated from the hysterectomy
date to recurrence or 31 March 2009. Both recurrence
and death due to any cause were considered as an event
for PFS. Overall survival (OS) was calculated from the
date of surgery to death or 31 March 2011 using death
due to any cause as an event. For survival analysis,
median value was used as cutoff for age, 5c ExR, and
9c ExR. The Kaplan–Meier method was used to
calculate the 5-year recurrence rate, PFS, and OS.
Log-rank test was used for univariate survival analysis.
Results
Histological review
After review and consensus discussion, all three or two of
the three pathologists agreed on the SAC diagnosis in 56
cases, which were included in further analyses. We used the
reviewed diagnosis as the basis for the present study as it
was found to be better in predicting prognosis in EC [15].
Patient characteristics
The median age of patients with SAC was 73 years (mean,
72; range, 56–89 years). There were 43 patients diagnosed
at stage IA, 8 at stage IB, and 5 at stage II (Table 1). There
was no myometrial invasion in 10 cases, invasion of less
than half the myometrial thickness in 34 cases, and more
than half in 12 cases. LVI was present in 17 cases. Recur-
rence was detected in 14 patients, of whom 2 had recurrence
in the vagina, 5 in the pelvis, and 7 outside the pelvis. The
majority of recurrences occurred in the first year after oper-
ation (eight cases); the earliest detected was after 3 months.
Table 1 Recurrence rate, progression-free survival, and overall survival based on clinical and pathological parameters in patients with stage I and II
serous adenocarcinoma



















Age <72 28 (50) 6 (21) 9 (32) 26±10 59±11 <0.01 69±10 <0.01
≥72 28 (50) 8 (29) 19 (68) 32±10 38±11 56±10
Stage IA 43 (77) 10 (23) 19 (44) 29±8 52±10 NS 69±8 NS
IB 8 (14) 1 (13) 5 (63) 17±15 25±20 38±17
II 5 (9) 3 (60) 4 (80) 60±22 40±22 40±22
Myometrial
invasion
No invasion 10 (18) 2 (20) 3 (30) 32±21 68±21 NS 90±10 NS
<Half
myometrium
34 (61) 9 (26) 17 (50) 30±9 45±11 60±9
>Half
myometrium
12 (21) 3 (25) 8 (67) 28±14 38±15 42±14
Adjuvant
therapy
Chemotherapy 19 (34) 6 (32) 8 (42) 40±14 60±14 0.02 78±10 0.04
Radiotherapy 10 (18) 0 3 (30) –b 79±13 80±13
Both 2 (4) 0 0 –b –b –b
No adjuvant
therapy
25 (45) 8 (32) 17 (68) 42±13 22±10 42±10
PFS progression-free survival, OS overall survival, SE standard error, NS not significant
a Overall p value by log-rank test
b No statistics were computed because all cases were censored
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DNA ploidy
The mean and median CVs of the diploid peaks were
3.02 and 2.80, respectively. The mean number of nuclei
analyzed was 1,005 (median, 1,192; range, 280–2,546).
The majority of tumors (n029, 52 %) were aneuploid,
of which 2 cases had DI≤1.20 and 27 cases had DI>
1.20. Tetraploidy and diploidy were detected in
8 (14 %) and 19 (34 %) tumors, respectively (Table 2).
Median 5c ExR was 2.28 (mean, 6.08 %; range, 0–
72.82 %). Median 9c ExR was 0.07 (mean, 0.42 %;
range, 0–13.76 %).
Immunohistochemistry
Immunohistochemistry was performed in 53 cases for p53, 52
cases for ER and PR, and 46 cases for Ki-67. The majority of
tumors (n034, 64 %) had strong nuclear expression of
Table 2 Recurrence rate, progression-free survival, and overall survival based on DNA ploidy and immunohistochemical markers in patients with
stage I and II serous adenocarcinoma



















Diploid 19 (34) 2 (11) 7 (37) 10±7 61±13 NS 71±11 NS
Aneuploid 29 (52) 8 (28) 15 (52) 38±13 43±12 64±9
Tetraploid 8 (14) 4 (50) 6 (75) 53±19 38±17 38±17
5c ExRb <2.28 % 28 (50) 4 (14) 10 (36) 15±7 58±11 <0.01 66±9 0.02
≥2.28 % 28 (50) 10 (36) 18 (64) 48±13 39±11 59±10
9c ExRb <0.07 % 27 (48) 5 (19) 12 (44) 28±10 51±11 NS 65±9 NS
≥0.07 % 29 (52) 9 (31) 16 (55) 33±11 45±12 59±10
P53 Negative
(≤10 %)
11 (21) 3 (27) 6 (55) 73±13 62±15 NS 82±12 NS
Weak (11–
50 %)




34 (64) 11 (32) 20 (59) 59±11 34±10 49±9
ER Negative
(≤10 %)
33 (63) 9 (27) 17 (52) 67±10 40±10 NS 54±9 NS
Weak (11–
50 %)




6 (12) 1 (17) 1 (17) 83±15 83±15 83±15
PR Negative
(≤10 %)
38 (73) 7 (18) 20 (53) 80±7 50±10 NS 58±8 NS
Weak (11–
50 %)




2 (4) 0 0 –c –c –c
Ki-67 Negative
(≤10 %)
1 (2) 0 1 (100) –c –c NS –c NS
Weak (11–
50 %)




24 (52) 2 (8) 8 (33) 90±7 74±9 75±9
PFS progression-free survival, OS overall survival, SE standard error, 5c ExR 5c exceeding rate, 9c ExR 9c exceeding rate, ER estrogen receptor, PR
progesterone receptor, NS not significant
a Overall p value by log-rank test
bMedian cutoff was used to group the cases
c No statistics were computed because all cases were censored
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p53 in >50% of cells. ER and PR expression in >50% of cells
was found in six (12 %) and two (4 %) tumors, respectively.
Ki-67 score >50 % was seen in 24 (52 %) cases (Table 2).
Survival analysis
Altogether, 14 patients had recurrent disease, and 28 patients
died during the follow-up period. The 5-year PFS and OS for
all cases were 48±9 and 62±7 %, respectively. Patients with
aneuploid and tetraploid tumors had a higher recurrence rate
and lower 5-year PFS and OS compared to patients with
diploid tumors (Table 2). DNA ploidy approached, but did
not reach statistical significance for recurrence (p00.09). A
DNA ploidy parameter, 5c ExR, was found to be prognos-
tic for 5-year recurrence rate (p00.03), PFS (p<0.01),
and OS (p00.02; Table 2, Fig. 1). p53, ER, PR, and Ki-
67 expression was unrelated to prognosis. Stage, the
extent of myometrial invasion, LVI, lymphadenectomy,
and the extent of hysterectomy failed to show prognostic
significance (Table 1). Shorter 5-year PFS (22 %) and OS
(42 %) were observed for patients who did not receive any
form of adjuvant therapy. Notably, patients who received
radiotherapy as adjuvant treatment had no recurrences.
Discussion
In this study, we evaluated the prognostic importance of
various clinical, pathological, DNA ploidy, and immunohis-
tochemical markers in early-stage SAC. The only significant
prognostic marker we found was the 5c ExR, a parameter
that can simply be extracted from a DNA ploidy analysis.
The explanation is that 5c ExR is high in proliferating
tetraploid tumors and aneuploid tumors with high DI.
Non-diploid tumors with low S-phase fraction and diploid
tumors show low 5c ExR. Therefore, less aggressive non-
diploid tumors are separated from highly aggressive tumors.
Earlier, Strang et al. reported that 5c ExR is a prognostic
parameter in patients with EC [16]. In our previous study, in
which exclusively endometrioid carcinoma was analyzed,
5c ExR (1 % as a cutoff) failed to show prognostic impor-
tance [13]; however, when the cutoff was changed to 2.28,
same as in this series, 5c ExR was a prognostic indicator
(unpublished data). Therefore, 5c ExR can be an objective
DNA ploidy parameter for patients with endometrial carci-
noma. Additionally, 5c ExR has also been found to be a
prognostic parameter in other cancers, e.g., non-small cell
lung carcinoma, uterine cervical carcinoma, neuroendocrine
tumors, and ependymoma [17–20]. There was also a ten-
dency, though not statistically significant, for patients with
diploid tumors to have lower recurrence rate and increased
overall survival. Kato et al. investigated 30 patients with
SAC in all stages and found no association between
aneuploidy and survival [21].
SAC is usually diagnosed based on morphology alone.
However, some tumors are difficult to classify due to over-
lapping features between SAC and EAC [22–24]. We
Fig. 1 Recurrence rate, progression-free survival, and overall survival
based on 5c exceeding rate in patients with serous adenocarcinoma
stage I and II
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observed lack of agreement in a substantial number of cases
at consensus session. This indicates that SAC, even after
being a distinct entity for more than 30 years, is not so easy
to diagnose morphologically in a certain number of cases.
Nordström et al. reported that 12 % of EC were reclassified
as SAC following histological review of 266 cases [25]. The
differential diagnosis of SAC included both benign and
malignant lesions, including EAC with small non-villous
papillae, papillary CAC, and malignant mullerian mixed
tumors [26]. Therefore, there is a need for ancillary techni-
ques for SAC diagnosis. Many pathologists use overexpres-
sion of p53 and Ki-67 together with underexpression of ER
and PR as additional diagnostic aids (Fig. 2). Since SAC is
associated with aneuploidy with DI >1.60, DNA ploidy
might also be a potential parameter supporting the diagnosis
[11]. There are reports on markers such as insulin-like
growth factor II mRNA-binding protein 3 which may be
useful in this differential diagnosis [27].
In EC, stage, myometrial invasion, and LVI are
established prognostic parameters [28]. However, these
parameters had no prognostic role in our series. Grade
and depth of myometrial invasion did not predict prog-
nosis in SAC in an earlier study, and these tumors are
currently not graded [21]. Goff et al. analyzed 50 cases
of SAC and similarly found no prognostic importance
for the depth of myometrial invasion [29].
p53 mutation is considered to be an early event in SAC
since it is found in serous intraepithelial carcinoma [7].
Usually, mutation leads to overexpression of mutant p53
protein which can be detected using immunohistochemistry.
However, nonsense mutation leads to total absence of pro-
tein expression [30]. Although overexpression of p53 has
been reported to be a prognostic factor in EC [31], p53
immunostaining was not informative of disease outcome in
the present series of SAC. This finding is similar to the
observation by Alkushi et al. where p53 overexpression
was not a prognostic indicator in patients with SAC but
was of prognostic importance in the analysis of patients
with low-grade EAC [32]. p53 expression may be help-
ful in morphologically ambiguous cases due to the
higher rate of overexpression in SAC [22]. ER and PR
are expressed in normal endometrial tissue, as well as in
the majority of EAC, mainly of low grade. In SAC, ER
and PR expression was found to be lower than in EAC
[33]. ER and PR expression was unrelated to prognosis
in our series. High expression of Ki-67, a proliferation
marker, was shown to be associated with poor prognosis
in patients with EC [31]. However, Ki-67 had no prog-
nostic value in our series of SAC.
In conclusion, established clinicopathological parameters
and immunohistochemical markers do not provide prognostic
information for patients in SAC stage I and II with high risk of
Fig. 2 a DNA ploidy histogram of an aneuploid serous adenocarcino-
ma showing high 5c ExR, strongly positive p53, and Ki-67 expression
and negative staining for estrogen and progesterone receptors. b A
diploid serous adenocarcinoma with low 5c ExR showing strong
expression of p53 and Ki-67 and weak expression of estrogen and
progesterone receptors. Benign glands are marked with red arrows
296 Virchows Arch (2012) 461:291–298
recurrence and death of disease. A DNA ploidy parameter, 5c
exceeding rate, may be a prognostic marker in this patient
group and should be further validated in larger series.
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